SCHEMBL1521812

SCHEMBL1521812

CCN1C(=O)N(c2ccc(F)c(NC(=O)Nc3cccc4ccccc34)c2)Cc2cnc(NC)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 1/20 0.40
PDGFRA P16234 1/20 0.40
TRPV1 Q8NER1 2/20 0.40
FGFR1 P11362 10/20 0.39
FGFR4 P22455 9/20 0.39
FGFR2 P21802 2/20 0.39
FGFR3 P22607 1/20 0.39
MAPT P10636 3/20 0.37
KRAS P01116 1/20 0.36
RAF1 P04049 1/20 0.36
BRAF P15056 1/20 0.36
KDR P35968 1/20 0.36
MAP2K2 P36507 1/20 0.36
MAP2K1 Q02750 1/20 0.36
KDM4E B2RXH2 2/20 0.36
LMNA P02545 1/20 0.36
NTRK1 P04629 1/20 0.35
CCKBR P32239 1/20 0.35
MEN1 O00255 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521657 0.89 TRPV1 (0.42) KITPDGFRATRPV1FGFR1FGFR4
SCHEMBL1521602 0.88 TRPV1 (0.40) KITPDGFRATRPV1FGFR1FGFR4
SCHEMBL1521817 0.85 BRAF (0.40) KITPDGFRAFGFR1FGFR4KRAS
SCHEMBL1521987 0.82 FGFR1 (0.43) KITPDGFRAFGFR1FGFR4FGFR2
SCHEMBL1521600 0.82 KRAS (0.37) KITPDGFRAFGFR1FGFR4FGFR2
SCHEMBL1521624 0.81 BRAF (0.44) KITPDGFRAFGFR1FGFR4FGFR2
SCHEMBL1521747 0.81 KIT (0.38) KITPDGFRAFGFR1FGFR4FGFR2
SCHEMBL1521993 0.81 KDR (0.39) KITPDGFRAFGFR1FGFR4KRAS
SCHEMBL1521807 0.81 MAPK14 (0.43) MAPTKRASRAF1BRAFKDR
SCHEMBL1521613 0.81 BRAF (0.42) KITPDGFRAFGFR1FGFR4FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
EP-2063896-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed
WO-2008033999-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 KIT 2755/4885PDGFRA 2199/4885TRPV1 1959/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 KIT 2755/4885PDGFRA 2199/4885TRPV1 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.